Achieve Life Sciences Receives CRL for Cytisinicline NDA After Third-Party CMO Receives OAI Classification

A manufacturing-site OAI classification has blocked approval of cytisinicline, underscoring how third-party CMO compliance status can derail an otherwise approvable NDA. Achieve Life Sciences received a Complete Response Letter from the FDA on June 22, 2026, with the agency citing cGMP deficiencies at the company's prior contract manufacturing facility and incomplete final product labeling, not clinical data, as the sole grounds for non-approval.

The FDA identified no deficiencies in cytisinicline's efficacy or safety profile, which is supported by two pivotal Phase 3 trials (ORCA-2 and ORCA-3) and a long-term open-label safety study covering more than 1,500 participants. The Official Action Indicated (OAI) classification applied to the prior facility addresses general cGMP matters unrelated to cytisinicline specifically, a distinction that matters for QA directors assessing how site-level observations propagate into product-specific review outcomes.

Achieve had anticipated this outcome. On April 15, 2026, the company disclosed it expected a CRL on or before its June 20, 2026 PDUFA date and had already initiated a CMO transition to U.S.-based Adare Pharma Solutions. Analytical method technology transfer to Adare's facility is complete, a first engineering batch has been manufactured, and all testing procedures have been fully qualified at the new site, a sequence that reflects the minimum readiness threshold FDA expects before a resubmission names a new primary manufacturer.

For plant heads and QA directors, the operational read is direct: OAI classifications at a contract site are not ring-fenced to that site's other clients. When an NDA lists a facility under OAI, the application carries that compliance burden regardless of whether the observations touch the specific drug product. Qualifying a backup manufacturing site and completing technology transfer before a PDUFA date is no longer a contingency measure, this case illustrates it as a baseline risk-mitigation requirement under 21 CFR Part 211 and ICH Q10 quality system expectations.

Achieve intends to resubmit the NDA in Q4 2026, naming Adare as primary commercial manufacturer, with a potential FDA approval targeted for the first half of 2027 and a subsequent U.S. commercial launch. The resubmission timeline will be a measurable indicator of how efficiently a completed technology transfer and a clean manufacturing site can convert a CRL into an approval cycle.

Source: Achieve Life Sciences, Inc. via GlobeNewswire, June 22, 2026.